In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...

UCB SA has a promising drug, Bimzelx, despite temporary EBITDA decline and potential regulatory hurdles ahead. Learn more ...

Oral Opportunity in PsO (US) 2024, highlights a shifting landscape in the treatment for moderate-to-severe PsO. As emerging oral therapies gain traction, the study underscores their potential to ...

Ventyx Biosciences (NASDAQ:VTYX – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, ...